Skip to main content
Log in

Initial Drug Dissolution from Amorphous Solid Dispersions Controlled by Polymer Dissolution and Drug-Polymer Interaction

  • Research Paper
  • Published:
Pharmaceutical Research Aims and scope Submit manuscript

Abstract

Purpose

To identify the key formulation factors controlling the initial drug and polymer dissolution rates from an amorphous solid dispersion (ASD).

Methods

Ketoconazole (KTZ) ASDs using PVP, PVP-VA, HMPC, or HPMC-AS as polymeric matrix were prepared. For each drug-polymer system, two types of formulations with the same composition were prepared: 1. Spray dried dispersion (SDD) that is homogenous at molecular level, 2. Physical blend of SDD (80% drug loading) and pure polymer (SDD-PB) that is homogenous only at powder level. Flory-Huggins interaction parameters (χ) between KTZ and the four polymers were obtained by Flory-Huggins model fitting. Solution 13C NMR and FT-IR were conducted to investigate the specific drug-polymer interaction in the solution and solid state, respectively. Intrinsic dissolution of both the drug and the polymer from ASDs were studied using a Higuchi style intrinsic dissolution apparatus. PXRD and confocal Raman microscopy were used to confirm the absence of drug crystallinity on the tablet surface before and after dissolution study.

Results

In solid state, KTZ is completely miscible with PVP, PVP-VA, or HPMC-AS, demonstrated by the negative χ values of −0.36, −0.46, −1.68, respectively; while is poorly miscible with HPMC shown by a positive χ value of 0.23. According to solution 13C NMR and FT-IR studies, KTZ interacts with HPMC-AS strongly through H-bonding and dipole induced interaction; with PVPs and PVP-VA moderately through dipole-induced interactions; and with HPMC weakly without detectable attractive interaction. Furthermore, the “apparent” strength of drug-polymer interaction, measured by the extent of peak shift on NMR or FT-IR spectra, increases with the increasing number of interacting drug-polymer pairs. For ASDs with the presence of considerable drug-polymer interactions, such as KTZ/PVPs, KTZ/PVP-VA, or KTZ /HPMC-AS systems, drug released at the same rate as the polymer when intimate drug-polymer mixing was ensured (i.e., the SDD systems); while drug released much slower than the polymer when molecular level mixing or drug-polymer interaction was absent (SDD-PB systems). For ASDs without drug-polymer interaction (i.e., KTZ/HPMC systems), the mixing homogeneity had little impact on the release rate of either the drug or the polymer thus SDD and SDD-PB demonstrated the same drug or polymer release rate, while the drug released slowly and independently of polymer release.

Conclusions

The initial drug release from an ASD was controlled by 1) the polymer release rate; 2) the strength of drug-polymer interaction, including the intrinsic interaction caused by the chemistry of the drug and the polymer (measured by the χ value), as well as that the apparent interaction caused by the drug-polymer ratio (measure by the extent of peak shift on spectroscopic analysis); and 3) the level of mixing homogeneity between the drug and polymer. In summary, the selection of polymer, drug-polymer ratio, and ASD processing conditions have profound impacts on the dissolution behavior of ASDs.

Relationship between initial drug and polymer dissolution rates from amorphous solid dispersions with different mixing uniformity and drug-polymer interactions

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9
Fig. 10
Fig. 11
Fig. 12
Fig. 13

Similar content being viewed by others

Abbreviations

ASD:

Amorphous solid dispersion

DSC:

Differential scanning calorimetry

ELSD:

Evaporative light scattering detector

FT-IR:

Fourier transform infrared spectroscopy

HPLC:

High performance liquid chromatography

HPMC:

Hydroxypropylmethylcellulose

HPMC-AS:

Hydroxypropylmethylcellulose acetate succinate

KTZ:

Ketoconazole

NMR:

Solution nuclear magnetic resonance

pIDR:

Pseudo intrinsic dissolution rate

PVP:

Polyvinylpyrrolidone

PVP-VA:

Vinylpyrrolidone-co-vinyl-acetate

PXRD:

Powder X-ray diffraction

R P/D :

The ratio of the normalized dissolution rates of polymer and drug

SDD:

Spray dried dispersion

SDD-PB:

Physical blend of SDD and pure polymer

SLS:

Sodium lauryl sulfate

UV:

Ultraviolet

χ:

Flory-Huggins interaction parameter

References

  1. Chiou WL, Riegelman S. Pharmaceutical applications of solid dispersion systems. J Pharm Sci. 1971;60:1281–302.

  2. Qian F, Huang J, Hussain MA. Drug–polymer solubility and miscibility: stability consideration and practical challenges in amorphous solid dispersion development. J Pharm Sci. 2010;99:2941–7.

    Article  CAS  PubMed  Google Scholar 

  3. Serajuddin ATM. Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs. J Pharm Sci. 1999;88:1058–66.

    Article  CAS  PubMed  Google Scholar 

  4. Newman A, Knipp G, Zografi G. Assessing the performance of amorphous solid dispersions. J Pharm Sci. 2012;101:1355–77.

    Article  CAS  PubMed  Google Scholar 

  5. Lian Y. Amorphous pharmaceutical solids: preparation, characterization and stabilization. Adv Drug Deliv Rev. 2001;48:27–42.

    Article  Google Scholar 

  6. Park K. Drug release mechanisms from amorphous solid dispersions. J Control Release. 2015;211:171.

    Article  CAS  PubMed  Google Scholar 

  7. Simonelli AP, Mehta SC, Higuchi WI. Dissolution rates of High Energy Polyvinylpyrrolidone (PVP) sulfathiazole coprecipitates. J Pharm Sci. 1969;58:538–49.

    Article  CAS  PubMed  Google Scholar 

  8. Simonelli AP, Mehta SC, Higuchi WI. Dissolution rates of high energy sulfathiazole-povidone coprecipitates 11: characterization of form of drug controlling its dissolution rate via solubility studies. J Pharm Sci. 1976;65:355–61.

    Article  CAS  PubMed  Google Scholar 

  9. Corrigan OI, Farvar MA, Higuchi WI. Drug membrane transport enhancement using high energy Drug Polyvinylpyrolidone (PVP) Co-precipitate. Int J Pharm. 1980;5:229–38.

    Article  CAS  Google Scholar 

  10. Jackson MJ, Toth SJ, Kestur US, Huang J, Qian F, Hussain MA, et al. Impact of polymers on the precipitation behavior of highly supersaturated aqueous danazol solutions. Mol Pharm. 2014;11:3027–38.

    Article  CAS  PubMed  Google Scholar 

  11. Ilevbareand GA, Taylor LS. Liquid–liquid phase separation in highly supersaturated aqueous solutions of poorly water-soluble drugs: implications for solubility enhancing formulations. Cryst Growth Des. 2013;13:1497–509.

    Article  Google Scholar 

  12. Ilevbare GA, Liu H, Edgar KJ, Taylor LS. Maintaining supersaturation in aqueous drug solutions: impact of different polymers on induction times. Cryst Growth Des. 2013;13:740–51.

    Article  CAS  Google Scholar 

  13. Hsieh Y-L, Ilevbare GA, Eerdenbrugh BV, Box KJ, Sanchez-Felix MV, Taylor LS. pH-induced precipitation behavior of weakly basic compounds: determination of extent and duration of supersaturation using potentiometric titration and correlation to solid state properties. Pharm Res. 2012;29:2738–53.

    Article  CAS  PubMed  Google Scholar 

  14. Murdande SB, Pikal MJ, Shanker RM, Bogner RH. Solubility advantage of amorphous pharmaceuticals, part 3: is maximum solubility advantage experimentally attainable and sustainable? J Pharm Sci. 2011;100:4349–56.

    Article  CAS  PubMed  Google Scholar 

  15. Guzmán HR, Tawa M, Zhang Z, Ratanabanangkoon P, Shaw P, Gardner CR, et al. Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulations. J Pharm Sci. 2007;96:2686–702.

    Article  PubMed  Google Scholar 

  16. Brouwers J, Brewster ME, Augustijns P. Supersaturating drug delivery systems: the answer to solubility-limited oral bioavailability? J Pharm Sci. 2009;98:2549–72.

    Article  CAS  PubMed  Google Scholar 

  17. Alonzo DE, Gao Y, Zhou D, Mo H, Zhang GGZ. Dissolution and precipitation behavior of amorphous solid dispersions. J Pharm Sci. 2011;100:3316–31.

    Article  CAS  PubMed  Google Scholar 

  18. Alonzo DE, Zhang GGZ, Zhou D, Gao Y. Understanding the behavior of amorphous pharmaceutical systems during dissolution. Pharm Res. 2010;27:608–18.

    Article  CAS  PubMed  Google Scholar 

  19. Liu C, Chen Z, Chen Y, Lu J, Li Y, Wang S, Wu G, Qian F. Improving oral bioavailability of Sorafenib by optimizing the “Spring” and “Parachute” based on molecular interaction mechanisms. Mol Pharm. 2016;13(2):599–608. doi:10.1021/acs.molpharmaceut.5b00837.

  20. Sunand DD, Lee PI. Probing the mechanisms of drug release from amorphous solid dispersions in medium-soluble and medium-insoluble carriers. J Control Release. 2015;211:85–93.

    Article  Google Scholar 

  21. Qian F, Wang J, Hartley R, Tao J, Haddadin R, Mathias N, et al. Solution behavior of PVP-VA and HPMC-AS-based amorphous solid dispersions and their bioavailability implications. Pharm Res. 2012;29:2766–76.

    Article  CAS  Google Scholar 

  22. Friesen DT, Shanker R, Crew M, Smithey DT, Curatolo WJ, Nightingale JAS. Hydroxypropyl methylcellulose acetate succinate-based spray-dried dispersions: an overview. Mol Pharm. 2008;5:1003–19.

    Article  CAS  PubMed  Google Scholar 

  23. Chen Y, Liu C, Chen Z, Su C, Hageman M, Hussain M, et al. Drug–polymer–water interaction and its implication for the dissolution performance of amorphous solid dispersions. Mol Pharm. 2015;12:576–89.

    Article  CAS  PubMed  Google Scholar 

  24. Qian F, Huang J, Zhu Q, Haddadin R, Gawel J, Garmise R, et al. Is a distinctive single Tg a reliable indicator for the homogeneity of amorphous solid dispersion? Int J Pharm. 2010;395:232–5.

    Article  CAS  PubMed  Google Scholar 

  25. Sun Y, Tao J, Zhang GGZ, Yu L. Solubilities of crystalline drugs in polymers: an improved analytical method and comparison of solubilities of indomethacin and nifedipine in PVP, PVP/VA, and PVAc. J Pharm Sci. 2010;99:4023–31.

    Article  CAS  PubMed  Google Scholar 

  26. Mooter GVD, Wuyts M, Blaton M, Busson R, Grobet P, Augustijns P, et al. Physical stabilisation of amorphous ketoconazole in solid dispersions with polyvinylpyrrolidone K25. Eur J Pharm Sci. 2001;12:261–9.

    Article  PubMed  Google Scholar 

  27. Wood JH, Syarto JE, Letterman H. Improved holder for intrinsic dissolution rate studies. J Pharm Sci. 1965;54:1068.

    Article  CAS  PubMed  Google Scholar 

  28. Huggins ML. Thermodynamic properties of solutions of long-chain compounds. Ann N Y Acad Sci. 1942;43:1–32.

    Article  CAS  Google Scholar 

Download references

ACKNOWLEDGMENTS AND DISCLOSURES

This research is supported by China National Nature Science Foundation (project number 81573355), and Bristol-Myers Squibb Company (Lawrenceville, NJ, USA). FQ also thank the start-up funds provided by the Center for Life Sciences at Tsinghua and Peking Universities (Beijing, China), and by the China Recruitment Program of Global Experts.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Feng Qian.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chen, Y., Wang, S., Wang, S. et al. Initial Drug Dissolution from Amorphous Solid Dispersions Controlled by Polymer Dissolution and Drug-Polymer Interaction. Pharm Res 33, 2445–2458 (2016). https://doi.org/10.1007/s11095-016-1969-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11095-016-1969-2

KEY WORDS

Navigation